Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITX24-01 in Severe Chronic Neck and Lower Back Pain
NCT07520240Phase 1Not yet recruiting
- Sponsor
- Interventional Analgesix Inc.
- Start
- Jun 2026
- Primary completion
- Jan 2027
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of resiniferatoxin in Facet arthropathy (FJOA) (4 arms), sponsored by Interventional Analgesix Inc. Primary endpoints: Safety of ITX24-01 or placebo up to 6 weeks and Tolerability of ITX24-01 or placebo up to 6 hours. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
resiniferatoxin
03
Conditions
Facet arthropathy (FJOA)
Beyond the preview
Go deeper on NCT07520240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07520240.